Core Viewpoint - MIRXES-B (02629) reported a mid-year performance for 2025, showing a revenue of $10.5 million, which represents a year-on-year increase of 9.4% [1] Financial Performance - The company reported a loss attributable to equity shareholders of approximately $28.35 million, which is a reduction of 36.22% compared to the previous year [1] - The loss per share is recorded at $0.185 [1] Revenue Drivers - The increase in revenue is primarily attributed to the growth in earnings from the early detection and precision multi-omics divisions, specifically from GASTROClearTM and LUNGClearTM products [1] - This revenue growth was partially offset by a decrease of $2.6 million in the infectious disease division due to the termination of FortitudeTM product sales [1]
MIRXES-B公布中期业绩 权益股东应占亏损约2835.23万美元 同比收窄36.22%